Vellingiri Raja Badrakalimuthu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vellingiri Raja Badrakalimuthu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Amit Chawla
1 shared publication- Andrew F. Tarbuck
Badrakalimuthu, Beechcroft, Fulbourn Hospital, Cambridge CB21 5EF, UK
1 shared publication Daphne Rumball
1 shared publication
Latest Publications
- Open Access
- 1 March 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (2) , 119-128
Anxiety: a hidden element in dementia
Summary: Anxiety has reported prevalence rates between 38 and 72% among people with dementia. It has a negative impact on cognitive impairment and is associated with agitation and poor quality of life. The presence of excessive anxiety can be difficult to establish in people with dementia, especially when expressive or receptive speech is impaired. Unfortunately, there is a lack of research on the treatment of anxiety in dementia, and also on the wider issue of the management of anxiety disorders in old age. We explore the prevalence, presentation and diagnosis of anxiety in dementia and discuss the therapeutic options available.
- 1 March 2012
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 18 (2) , 119-128
Open AccessAnxiety: a hidden element in dementia
Summary: Anxiety has reported prevalence rates between 38 and 72% among people with dementia. It has a negative impact on cognitive impairment and is associated with agitation and poor quality of life. The presence of excessive anxiety can be difficult to establish in people with dementia, especially when expressive or receptive speech is impaired. Unfortunately, there is a lack of research on the treatment of anxiety in dementia, and also on the wider issue of the management of anxiety disorders in old age. We explore the prevalence, presentation and diagnosis of anxiety in dementia and discuss the therapeutic options available.
- 1 September 2011
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 17 (5) , 340-349
Hepatitis C: a patient's journey from a psychiatrist's perspective
Summary: There is an increasing prevalence of hepatitis C, particularly among intravenous drug users. Estimates of infection with the hepatitis C virus (HCV) in patients with severe mental illness in the USA have ranged from 8.5% to 19.6%. Alcohol use and misuse is the single biggest contributory factor to the development of fatal liver disease in people with hepatitis C. Neuropsychiatric symptoms are present in HCV infection, independent of any treatment. Despite such alarming observations, the success rate of antiviral treatment in chronic hepatitis C has improved considerably in recent years. This article explores psychiatrists' involvement in advocating for treatment inclusion, assessing patients' capacity to make treatment-related decisions and supporting the medical team in managing the complex journey a patient undertakes from being at high risk to receiving treatment for neuropsychiatric symptoms.
- 1 September 2011
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 17 (5) , 340-349
Hepatitis C: a patient's journey from a psychiatrist's perspective
Summary: There is an increasing prevalence of hepatitis C, particularly among intravenous drug users. Estimates of infection with the hepatitis C virus (HCV) in patients with severe mental illness in the USA have ranged from 8.5% to 19.6%. Alcohol use and misuse is the single biggest contributory factor to the development of fatal liver disease in people with hepatitis C. Neuropsychiatric symptoms are present in HCV infection, independent of any treatment. Despite such alarming observations, the success rate of antiviral treatment in chronic hepatitis C has improved considerably in recent years. This article explores psychiatrists' involvement in advocating for treatment inclusion, assessing patients' capacity to make treatment-related decisions and supporting the medical team in managing the complex journey a patient undertakes from being at high risk to receiving treatment for neuropsychiatric symptoms.